Beleave Kannabis Corp.

publicPublic Group

Beleave is an ISO certified, Canadian cannabis company headquartered in the Greater Toronto Area that cultivates high-quality cannabis flower, oil and extracts for medical and recreational markets. Beleave is fully licenced to cultivate and sell medical and recreational cannabis and is leading ...

people3 Members       (0)

Corporate Profile
Group Admins:
  • Thumb 8020 monitor 200200 2
Add Corporate Feed


Beleave Kannabis Corp.

publicPublicGroup

Beleave is an ISO certified, Canadian cannabis company headquartered in the Greater Toronto Area that cultivates high......

people3 Members       (0)

Thumb 8020 monitor 200200 2

8020 Admin

21 hours ago

8020 Admin posted a press release Beleave Announces Joint Venture with Volero Brands to Launch Cannabis 2.0 Products in Canada in BELEAVE KANNABIS CORP.

Toronto, Ontario--(Newsfile Corp. - October 31, 2019) - Beleave Inc. (CSE: BE) (OTC: BLEVF) ("Beleave" or the "Company") and Volero Brands Inc. ("Volero") are pleased to announce that they have entered into a definitive agreement (the "Joint Venture Agreement") to form a joint venture (the "Joint Venture" or "Partnership") to develop, produce, and distribute cannabis extracts, topicals and edibles for the Canadian market.


"Innovation, strong leadership, and the ability to navigate the regulatory landscape are core capabilities required for differentiation and future success in the rapidly evolving Canadian cannabis market," said Jeannette VanderMarel, Beleave CEO. "We are thrilled to be working with Sean and the Volero team as they have an unparalleled depth of knowledge and experience in the cannabis space. Our partnership with Volero will allow us to effectively produce the quality products clients and patients have come to expect from Beleave."


"We're excited to partner with Beleave and bring an entirely new product category to the Canadian market. Our team knows that the best results are delivered when great people come together to collaborate with a common vision. This is exactly the environment we have right now with the team at Beleave," said Sean Trustham, Volero CEO. "This is just the beginning. As we continue to develop and introduce unique products in the coming months, we will keep setting ourselves and our brands apart to ensure that, in the end, we will have fully leveraged this opportunity to establish a leading position in the cannabis extracts markets."


Canadians are increasingly looking for new and safe ways to consume cannabis, and this partnership allows Beleave to meet that need while maintaining strict protocols and introducing standardized products with higher margins. Cannabis 2.0 regulations are in response to a significant and unmet demand in the legal medical cannabis market to provide more flexibility in how cannabis is consumed.


Leveraging Beleave's production capacity, scale, reach, and sales network to drive growth for new products in the Canadian market, the Partnership outlines plans for the roll-out of extracts, topicals and edibles throughout 2020, beginning with Flyte vape pens in December 2019. Launching with six flavours, Flyte pens and refill cartridges are the first of a broader line of cannabinoid-based products Beleave and Volero intend to launch in the future.


"The cannabis concentrate that will be sold in Flyte vapes will meet federal quality regulations as outlined by Health Canada," said Dr. Roger Ferreira, Beleave's Chief Science Officer. "When you extract and concentrate cannabis, you're able to deliver the active ingredient as a more potent formulation. We start with cannabis that is rigorously tested and free from pesticides and heavy metals to ensure a clean and safe end product. We work hard to produce high quality, standardized products to meet the demands of our clients and patients, with safety top of mind."


The first release of Flyte vape pen cartridges will be sold in 0.5 gram net weight units (kits include slim-form 100mAh batteries). Each cartridge will contain 300 mg of THC. Like all Beleave products, Flyte pens will come with publicly available, independent laboratory analysis reports on cannabinoid potency, terpene profiles, as well as pesticide and contaminant screening.


On October 30, Beleave announced it had received an amendment to its processing license from Health Canada to authorize the sale of cannabis extracts, topicals and edible cannabis products to provincially and territorially authorized retailers. The amendment allows Beleave to participate in the newly announced Cannabis 2.0 regulations that went into effect October 17, 2019. Companies must give notice to Health Canada about new products and Beleave has already submitted the required 60-day notification, with sales anticipated to begin this December through Beleave's existing sales and distribution channels.


About Volero Brands


Volero Brands is a privately held, British Columbia-based company engaged in the development of a family of cannabis brands and delivery systems for Canadian and international markets. The Company's flagship brand is Flyte, a suite of top-quality cannabis distillate products. The Flyte brand and expertise has been licensed in the state of Nevada for concentrates prepared from distillates of phytocannabinoids and packaged in vaporizer pen cartridges. The Company brings deep technical and brand expertise to extraction, formulation, development and marketing of cannabis distillate-based products.


About Beleave Inc.


Beleave is an ISO certified, Canadian cannabis company headquartered in the Greater Toronto Area that cultivates high-quality cannabis flower, oil and extracts for medical and recreational markets. Beleave is fully licenced to cultivate and sell medical and recreational cannabis and is leading the way through research partnerships with universities to develop pharma-grade extracts and derivatives.


Beleave is developing new product lines, including cannabis-infused products, oils, vape pens, and other novel cannabis delivery methods for 2019. Beleave has developed a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner.


Investor Relations Contact:


Kevin Keagan
Interim Chief Financial Officer
Phone: 1 (647) 449 - 7352
Email: kkeagan@beleave.com


Forward-Looking Statements


This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speaks only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com.



To view the source version of this press release, please visit https://www.newsfilecorp.com/release/49299

!
Thumb 8020 monitor 200200 2

8020 Admin

1 day ago

8020 Admin posted a press release Beleave Receives License to Sell Cannabis Extracts, Topicals and Edibles in BELEAVE KANNABIS CORP.

Toronto, Ontario--(Newsfile Corp. - October 30, 2019) - Beleave Inc. (CSE: BE) (OTC: BLEVF) ("Beleave" or the "Company") is pleased to announce that its wholly-owned subsidiary Beleave Kannabis Corp. has received an amendment to its processing license from Health Canada for its ISO certified facility in Hamilton, Ontario to authorize the sale of cannabis extracts, topicals and edible products to provincially and territorially authorized retailers and holders of a license for sale for medical purposes.


The amended standard processing license is in addition to the previously granted license for standard cultivation, license for sale for medical purposes, and research license issued under the Cannabis Regulations.


"Adding cannabis extracts, topicals and edibles to our product line allows Beleave to improve the way we meet the needs of our patients and customers," said Dr. Roger Ferreira, Beleave's Chief Science Officer. "Canadians are increasingly looking for new and safe ways to consume cannabis, and this new license allows us to pursue that vision while maintaining strict protocols and introducing standardized products in high-margin categories."


This approval is significant as it allows Beleave to participate in the newly announced Cannabis 2.0 regulations that went into effect October 17, 2019. The Company has already submitted the required 60-day notification to Health Canada for 8 new extract product SKUs, with sales anticipated to begin this December.


ABOUT BELEAVE INC.
Beleave is an ISO certified, Canadian cannabis company headquartered in the Greater Toronto Area that cultivates high-quality cannabis flower, oil and extracts for medical and recreational markets. Beleave is fully licensed to cultivate and sell medical and recreational cannabis and is leading the way through research partnerships with universities to develop pharma-grade extracts and derivatives.


Beleave is developing new product lines, including cannabis-infused products, oils, vape pens, and other novel cannabis delivery methods for 2019. Beleave has developed a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner.


Investor Relations Contact:
Kevin Keagan
Interim Chief Financial Officer
Phone: 1 (647) 449 - 7352
Email: kkeagan@beleave.com


Forward-Looking Statements


This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speaks only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com.



To view the source version of this press release, please visit https://www.newsfilecorp.com/release/49280

!
Thumb 8020 monitor 200200 2

8020 Admin

2 days ago

8020 Admin posted a press release Beleave Announces Date of 2019 Annual General Meeting in BELEAVE KANNABIS CORP.

Toronto, Ontario--(Newsfile Corp. - October 30, 2019) - Beleave Inc. (CSE: BE) (OTC: BLEVF) ("Beleave" or the "Company") is pleased to announce that it will hold its Annual General Meeting ("AGM" or "Meeting") on December 2, 2019 in Toronto, Ontario.


Shareholders and management will be meeting to review and discuss the following:



  • to receive the audited financial statements of the Company for the year ended March 31, 2019, and the report of the auditors thereon;

  • to elect directors of the Company for the ensuing year;

  • to appoint McGovern Hurley LLP as auditors of the Company and to authorize the board of directors to fix their remuneration;

  • to consider and, if deemed appropriate, to approve an amendment to the Company's "fixed" stock option plan ("the Amended Plan") to increase the number of shares authorized for issuance under the plan; and amend the cancellation of vested options from 90 days following termination or resignation to coincide with the expiration upon issuance;

  • to consider and, if deemed appropriate, pass a special resolution, the full text of which is set out in the Circular authorizing the directors of the Company to amend the Company's Articles of Incorporation to consolidate the number of issued and outstanding Common Shares by a ratio of up to 10:1 at the discretion of the board of directors, as more fully described in the section of the Circular entitled "Matters to Be Acted Upon At the Meeting - Stock Consolidation"; and

  • to transact such other business as may properly come before the Meeting or any adjournment or postponement thereof.


Similar to the AGM's of prior years, most of Beleave's senior management team will be in attendance to meet with shareholders and answer questions.


Right to Attend Notification


The record date for determining the shareholders entitled to receive notice of and vote at the Meeting is the close of business on October 28, 2019 (the "Record Date"). Only shareholders whose names have been entered in the applicable register of Shareholders as of 5:00 p.m. (Eastern Time) on the Record Date are entitled to receive notice of and vote at the Meeting.


Those shareholders of record will be included in the list of Shareholders prepared as at the Record Date and will be entitled to vote the Common Shares recorded therein at the Meeting.


Annual General Meeting Details


Date: December 2, 2019
Time: 10:00 a.m. (Eastern Time)
Location: Bennett Jones LLP, 1 First Canadian Place, Suite 3400, Toronto, Ontario, M5X 1A4


ABOUT BELEAVE INC.


Beleave is an ISO certified, Canadian cannabis company headquartered in the Greater Toronto Area that cultivates high-quality cannabis flower, oil and extracts for medical and recreational markets. Beleave is fully licenced to cultivate and sell medical and recreational cannabis and is leading the way through research partnerships with universities to develop pharma-grade extracts and derivatives.


Beleave is developing new product lines, including cannabis-infused products, oils, vape pens, and other novel cannabis delivery methods for 2019. Beleave has developed a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner. The Company has partnered with Canymed GmbH to supply the German market with medical cannabis.


Investor Relations Contact:

Kevin Keagan

Interim Chief Financial Officer

Phone: 1 (647) 449 - 7352

Email: kkeagan@beleave.com

Forward-Looking Statements


This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speaks only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com.



To view the source version of this press release, please visit https://www.newsfilecorp.com/release/49259

!
Thumb 8020 monitor 200200 2

8020 Admin

2 days ago

8020 Admin posted a press release Beleave Appoints Jeannette VanderMarel to Board of Directors in BELEAVE KANNABIS CORP.

Toronto, Ontario--(Newsfile Corp. - October 29, 2019) - Beleave Inc. (CSE: BE) (OTC: BLEVF) ("Beleave" or the "Company") is pleased to announce updates to its Board of Directors (the "Board"), taking effect today. The Company has elected newly appointed Beleave CEO Jeannette VanderMarel to the Board.


"I look forward to working with my other Board members as we move towards Beleave's next phase of growth and market leadership," commented Ms. VanderMarel. "Beleave is an excellent company with tremendous value creation opportunities on the horizon. Our board and management team are committed to achieving outstanding performance and maximizing shareholder value."


Ms. VanderMarel will be replacing Amy Nederlander and James Wasserstrom, who stepped down from the Board on October 23rd and October 28th respectively. Beleave's other Directors consist of Kevin Keagan, Vasilios (Bill) Panagiotakopoulos, Andrew Steane, and Roger Ferreira.


About Jeannette VanderMarel


As an early mover in the Canadian cannabis industry, Jeannette VanderMarel was the Co-CEO of 48 North Cannabis, Co-Founder and President of Good & Green, and Co-Founder of The Green Organic Dutchman. Motivated by her first-hand experience, she has a strong passion for, and commitment to, the cannabis industry, recognizing the opportunity cannabis presents to improve patients' lives, combat the growing reliance on opiates, and improve wellness and health by offering new and innovative treatment alternatives.


Ms. VanderMarel is a certified CNCCP(C) through the Canadian Nurses Association, registered nurse, popular keynote speaker, and makes frequent TV and print media appearances as she shares her thoughts and knowledge on cannabis-related news.


ABOUT BELEAVE INC.
Beleave is an ISO certified, Canadian cannabis company headquartered in the Greater Toronto Area that cultivates high-quality cannabis flower, oil and extracts for medical and recreational markets. Beleave is fully licensed to cultivate and sell medical and recreational cannabis and is leading the way through research partnerships with universities to develop pharma-grade extracts and derivatives.


Beleave is developing new product lines, including cannabis-infused products, oils, vape pens, and other novel cannabis delivery methods for 2019. Beleave has developed a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner. The Company has partnered with Canymed GmbH to supply the German market with medical cannabis.


Investor Relations Contact:
Kevin Keagan
Interim Chief Financial Officer
Phone: 1 (647) 449 - 7352
Email: kkeagan@beleave.com


Forward-Looking Statements


This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speaks only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com.



To view the source version of this press release, please visit https://www.newsfilecorp.com/release/49248

!
Thumb 8020 monitor 200200 2

8020 Admin

4 days ago

8020 Admin posted a press release Beleave Appoints Jeannette VanderMarel Chief Executive Officer in BELEAVE KANNABIS CORP.

Toronto, Ontario--(Newsfile Corp. - October 28, 2019) - Beleave's (CSE: BE) (OTCQX: BLEVF) ("Beleave" or the "Company") Board of Directors announced that Jeannette VanderMarel has been appointed the Company's Chief Executive Officer. Bill Panagiotakopoulos, who took over as CEO earlier this year, will return to his role as Beleave's COO. These changes are effective today.


"I am proud and thrilled to be adding my skills and investment to the Beleave team," said Ms. VanderMarel. "This is an exciting time in the cannabis marketplace and our investors, employees, partners, and customers are looking for us to drive innovation and growth in this new era. Beleave is ideally positioned to capitalize on the many opportunities that are ahead of us, and I'm excited to be working with the leadership team to realize that potential."


"Jeannette has a phenomenal track-record and has been instrumental in originating and building successful businesses for years in the cannabis sector. She has a strong command of our industry and a proven ability to drive results," said Kevin Keagan, interim CFO at Beleave. "I am proud that Jeannette will lead our company, and our entire leadership team is excited to work with her to ensure a seamless transition as we move towards Beleave's next phase of growth and market leadership."


As an early mover in the Canadian cannabis industry, Ms. VanderMarel was the Co-CEO of 48 North Cannabis, Co-Founder and President of Good & Green, and Co-Founder of The Green Organic Dutchman. Motivated by her first-hand experience, Jeannette has a strong passion for, and commitment to, the cannabis industry, recognizing the opportunity cannabis presents to improve patients' lives, combat the growing reliance on opiates, and improve wellness and health by offering new and innovative treatment alternatives. She is a certified CNCCP(C) through the Canadian Nurses Association, registered nurse, popular keynote speaker, and makes frequent TV and print media appearances as she shares her thoughts and knowledge on cannabis-related news.


"At the same time, we are happy that we will continue to benefit from Bill's experience as he returns to his role as Beleave's Chief Operations Officer," added Keagan. "He has been an exemplary leader during this time of transition, with a steadfast commitment to driving Beleave's business and building on our strong momentum. We are grateful for his leadership and stewardship. With Jeannette as CEO and Bill as COO, Beleave has a great advantage in our marketplace."


ABOUT BELEAVE INC.


Beleave is an ISO certified, Canadian cannabis company headquartered in the Greater Toronto Area that cultivates high-quality cannabis flower, oil and extracts for medical and recreational markets. Beleave is fully licenced to cultivate and sell medical and recreational cannabis and is leading the way through research partnerships with universities to develop pharma-grade extracts and derivatives.


Beleave is developing new product lines, including cannabis-infused products, oils, vape pens, and other novel cannabis delivery methods for 2019. Beleave has developed a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner. Beleave has partnered with Canymed GmbH to supply the German market with medical cannabis


Investor Relations Contact:
Kevin Keagan
Interim Chief Financial Officer
Phone: 1 (647) 449 - 7352
Email: kkeagan@beleave.com


Forward-Looking Statements


This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speaks only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com.



To view the source version of this press release, please visit https://www.newsfilecorp.com/release/49179

!

Beleave Kannabis Corp.

publicPublic Group

Beleave is an ISO certified, Canadian cannabis company headquartered in the Greater Toronto Area that cultivates high-quality cannabis flower, oil and extracts for medical and recreational markets. Beleave is fully licenced to cultivate and sell medical and recreational cannabis and is leading ...

people3 Members       (0)

Corporate Profile
Group Admins:
  • Thumb 8020 monitor 200200 2
Add Corporate Feed


Beleave Kannabis Corp.

publicPublicGroup

Beleave is an ISO certified, Canadian cannabis company headquartered in the Greater Toronto Area that cultivates high......

people3 Members       (0)

Thumb 8020 monitor 200200 2

8020 Admin

21 hours ago

8020 Admin posted a press release Beleave Announces Joint Venture with Volero Brands to Launch Cannabis 2.0 Products in Canada in BELEAVE KANNABIS CORP.

Toronto, Ontario--(Newsfile Corp. - October 31, 2019) - Beleave Inc. (CSE: BE) (OTC: BLEVF) ("Beleave" or the "Company") and Volero Brands Inc. ("Volero") are pleased to announce that they have entered into a definitive agreement (the "Joint Venture Agreement") to form a joint venture (the "Joint Venture" or "Partnership") to develop, produce, and distribute cannabis extracts, topicals and edibles for the Canadian market.


"Innovation, strong leadership, and the ability to navigate the regulatory landscape are core capabilities required for differentiation and future success in the rapidly evolving Canadian cannabis market," said Jeannette VanderMarel, Beleave CEO. "We are thrilled to be working with Sean and the Volero team as they have an unparalleled depth of knowledge and experience in the cannabis space. Our partnership with Volero will allow us to effectively produce the quality products clients and patients have come to expect from Beleave."


"We're excited to partner with Beleave and bring an entirely new product category to the Canadian market. Our team knows that the best results are delivered when great people come together to collaborate with a common vision. This is exactly the environment we have right now with the team at Beleave," said Sean Trustham, Volero CEO. "This is just the beginning. As we continue to develop and introduce unique products in the coming months, we will keep setting ourselves and our brands apart to ensure that, in the end, we will have fully leveraged this opportunity to establish a leading position in the cannabis extracts markets."


Canadians are increasingly looking for new and safe ways to consume cannabis, and this partnership allows Beleave to meet that need while maintaining strict protocols and introducing standardized products with higher margins. Cannabis 2.0 regulations are in response to a significant and unmet demand in the legal medical cannabis market to provide more flexibility in how cannabis is consumed.


Leveraging Beleave's production capacity, scale, reach, and sales network to drive growth for new products in the Canadian market, the Partnership outlines plans for the roll-out of extracts, topicals and edibles throughout 2020, beginning with Flyte vape pens in December 2019. Launching with six flavours, Flyte pens and refill cartridges are the first of a broader line of cannabinoid-based products Beleave and Volero intend to launch in the future.


"The cannabis concentrate that will be sold in Flyte vapes will meet federal quality regulations as outlined by Health Canada," said Dr. Roger Ferreira, Beleave's Chief Science Officer. "When you extract and concentrate cannabis, you're able to deliver the active ingredient as a more potent formulation. We start with cannabis that is rigorously tested and free from pesticides and heavy metals to ensure a clean and safe end product. We work hard to produce high quality, standardized products to meet the demands of our clients and patients, with safety top of mind."


The first release of Flyte vape pen cartridges will be sold in 0.5 gram net weight units (kits include slim-form 100mAh batteries). Each cartridge will contain 300 mg of THC. Like all Beleave products, Flyte pens will come with publicly available, independent laboratory analysis reports on cannabinoid potency, terpene profiles, as well as pesticide and contaminant screening.


On October 30, Beleave announced it had received an amendment to its processing license from Health Canada to authorize the sale of cannabis extracts, topicals and edible cannabis products to provincially and territorially authorized retailers. The amendment allows Beleave to participate in the newly announced Cannabis 2.0 regulations that went into effect October 17, 2019. Companies must give notice to Health Canada about new products and Beleave has already submitted the required 60-day notification, with sales anticipated to begin this December through Beleave's existing sales and distribution channels.


About Volero Brands


Volero Brands is a privately held, British Columbia-based company engaged in the development of a family of cannabis brands and delivery systems for Canadian and international markets. The Company's flagship brand is Flyte, a suite of top-quality cannabis distillate products. The Flyte brand and expertise has been licensed in the state of Nevada for concentrates prepared from distillates of phytocannabinoids and packaged in vaporizer pen cartridges. The Company brings deep technical and brand expertise to extraction, formulation, development and marketing of cannabis distillate-based products.


About Beleave Inc.


Beleave is an ISO certified, Canadian cannabis company headquartered in the Greater Toronto Area that cultivates high-quality cannabis flower, oil and extracts for medical and recreational markets. Beleave is fully licenced to cultivate and sell medical and recreational cannabis and is leading the way through research partnerships with universities to develop pharma-grade extracts and derivatives.


Beleave is developing new product lines, including cannabis-infused products, oils, vape pens, and other novel cannabis delivery methods for 2019. Beleave has developed a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner.


Investor Relations Contact:


Kevin Keagan
Interim Chief Financial Officer
Phone: 1 (647) 449 - 7352
Email: kkeagan@beleave.com


Forward-Looking Statements


This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speaks only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com.



To view the source version of this press release, please visit https://www.newsfilecorp.com/release/49299

!
Thumb 8020 monitor 200200 2

8020 Admin

1 day ago

8020 Admin posted a press release Beleave Receives License to Sell Cannabis Extracts, Topicals and Edibles in BELEAVE KANNABIS CORP.

Toronto, Ontario--(Newsfile Corp. - October 30, 2019) - Beleave Inc. (CSE: BE) (OTC: BLEVF) ("Beleave" or the "Company") is pleased to announce that its wholly-owned subsidiary Beleave Kannabis Corp. has received an amendment to its processing license from Health Canada for its ISO certified facility in Hamilton, Ontario to authorize the sale of cannabis extracts, topicals and edible products to provincially and territorially authorized retailers and holders of a license for sale for medical purposes.


The amended standard processing license is in addition to the previously granted license for standard cultivation, license for sale for medical purposes, and research license issued under the Cannabis Regulations.


"Adding cannabis extracts, topicals and edibles to our product line allows Beleave to improve the way we meet the needs of our patients and customers," said Dr. Roger Ferreira, Beleave's Chief Science Officer. "Canadians are increasingly looking for new and safe ways to consume cannabis, and this new license allows us to pursue that vision while maintaining strict protocols and introducing standardized products in high-margin categories."


This approval is significant as it allows Beleave to participate in the newly announced Cannabis 2.0 regulations that went into effect October 17, 2019. The Company has already submitted the required 60-day notification to Health Canada for 8 new extract product SKUs, with sales anticipated to begin this December.


ABOUT BELEAVE INC.
Beleave is an ISO certified, Canadian cannabis company headquartered in the Greater Toronto Area that cultivates high-quality cannabis flower, oil and extracts for medical and recreational markets. Beleave is fully licensed to cultivate and sell medical and recreational cannabis and is leading the way through research partnerships with universities to develop pharma-grade extracts and derivatives.


Beleave is developing new product lines, including cannabis-infused products, oils, vape pens, and other novel cannabis delivery methods for 2019. Beleave has developed a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner.


Investor Relations Contact:
Kevin Keagan
Interim Chief Financial Officer
Phone: 1 (647) 449 - 7352
Email: kkeagan@beleave.com


Forward-Looking Statements


This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speaks only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com.



To view the source version of this press release, please visit https://www.newsfilecorp.com/release/49280

!
Thumb 8020 monitor 200200 2

8020 Admin

2 days ago

8020 Admin posted a press release Beleave Announces Date of 2019 Annual General Meeting in BELEAVE KANNABIS CORP.

Toronto, Ontario--(Newsfile Corp. - October 30, 2019) - Beleave Inc. (CSE: BE) (OTC: BLEVF) ("Beleave" or the "Company") is pleased to announce that it will hold its Annual General Meeting ("AGM" or "Meeting") on December 2, 2019 in Toronto, Ontario.


Shareholders and management will be meeting to review and discuss the following:



  • to receive the audited financial statements of the Company for the year ended March 31, 2019, and the report of the auditors thereon;

  • to elect directors of the Company for the ensuing year;

  • to appoint McGovern Hurley LLP as auditors of the Company and to authorize the board of directors to fix their remuneration;

  • to consider and, if deemed appropriate, to approve an amendment to the Company's "fixed" stock option plan ("the Amended Plan") to increase the number of shares authorized for issuance under the plan; and amend the cancellation of vested options from 90 days following termination or resignation to coincide with the expiration upon issuance;

  • to consider and, if deemed appropriate, pass a special resolution, the full text of which is set out in the Circular authorizing the directors of the Company to amend the Company's Articles of Incorporation to consolidate the number of issued and outstanding Common Shares by a ratio of up to 10:1 at the discretion of the board of directors, as more fully described in the section of the Circular entitled "Matters to Be Acted Upon At the Meeting - Stock Consolidation"; and

  • to transact such other business as may properly come before the Meeting or any adjournment or postponement thereof.


Similar to the AGM's of prior years, most of Beleave's senior management team will be in attendance to meet with shareholders and answer questions.


Right to Attend Notification


The record date for determining the shareholders entitled to receive notice of and vote at the Meeting is the close of business on October 28, 2019 (the "Record Date"). Only shareholders whose names have been entered in the applicable register of Shareholders as of 5:00 p.m. (Eastern Time) on the Record Date are entitled to receive notice of and vote at the Meeting.


Those shareholders of record will be included in the list of Shareholders prepared as at the Record Date and will be entitled to vote the Common Shares recorded therein at the Meeting.


Annual General Meeting Details


Date: December 2, 2019
Time: 10:00 a.m. (Eastern Time)
Location: Bennett Jones LLP, 1 First Canadian Place, Suite 3400, Toronto, Ontario, M5X 1A4


ABOUT BELEAVE INC.


Beleave is an ISO certified, Canadian cannabis company headquartered in the Greater Toronto Area that cultivates high-quality cannabis flower, oil and extracts for medical and recreational markets. Beleave is fully licenced to cultivate and sell medical and recreational cannabis and is leading the way through research partnerships with universities to develop pharma-grade extracts and derivatives.


Beleave is developing new product lines, including cannabis-infused products, oils, vape pens, and other novel cannabis delivery methods for 2019. Beleave has developed a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner. The Company has partnered with Canymed GmbH to supply the German market with medical cannabis.


Investor Relations Contact:

Kevin Keagan

Interim Chief Financial Officer

Phone: 1 (647) 449 - 7352

Email: kkeagan@beleave.com

Forward-Looking Statements


This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speaks only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com.



To view the source version of this press release, please visit https://www.newsfilecorp.com/release/49259

!
Thumb 8020 monitor 200200 2

8020 Admin

2 days ago

8020 Admin posted a press release Beleave Appoints Jeannette VanderMarel to Board of Directors in BELEAVE KANNABIS CORP.

Toronto, Ontario--(Newsfile Corp. - October 29, 2019) - Beleave Inc. (CSE: BE) (OTC: BLEVF) ("Beleave" or the "Company") is pleased to announce updates to its Board of Directors (the "Board"), taking effect today. The Company has elected newly appointed Beleave CEO Jeannette VanderMarel to the Board.


"I look forward to working with my other Board members as we move towards Beleave's next phase of growth and market leadership," commented Ms. VanderMarel. "Beleave is an excellent company with tremendous value creation opportunities on the horizon. Our board and management team are committed to achieving outstanding performance and maximizing shareholder value."


Ms. VanderMarel will be replacing Amy Nederlander and James Wasserstrom, who stepped down from the Board on October 23rd and October 28th respectively. Beleave's other Directors consist of Kevin Keagan, Vasilios (Bill) Panagiotakopoulos, Andrew Steane, and Roger Ferreira.


About Jeannette VanderMarel


As an early mover in the Canadian cannabis industry, Jeannette VanderMarel was the Co-CEO of 48 North Cannabis, Co-Founder and President of Good & Green, and Co-Founder of The Green Organic Dutchman. Motivated by her first-hand experience, she has a strong passion for, and commitment to, the cannabis industry, recognizing the opportunity cannabis presents to improve patients' lives, combat the growing reliance on opiates, and improve wellness and health by offering new and innovative treatment alternatives.


Ms. VanderMarel is a certified CNCCP(C) through the Canadian Nurses Association, registered nurse, popular keynote speaker, and makes frequent TV and print media appearances as she shares her thoughts and knowledge on cannabis-related news.


ABOUT BELEAVE INC.
Beleave is an ISO certified, Canadian cannabis company headquartered in the Greater Toronto Area that cultivates high-quality cannabis flower, oil and extracts for medical and recreational markets. Beleave is fully licensed to cultivate and sell medical and recreational cannabis and is leading the way through research partnerships with universities to develop pharma-grade extracts and derivatives.


Beleave is developing new product lines, including cannabis-infused products, oils, vape pens, and other novel cannabis delivery methods for 2019. Beleave has developed a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner. The Company has partnered with Canymed GmbH to supply the German market with medical cannabis.


Investor Relations Contact:
Kevin Keagan
Interim Chief Financial Officer
Phone: 1 (647) 449 - 7352
Email: kkeagan@beleave.com


Forward-Looking Statements


This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speaks only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com.



To view the source version of this press release, please visit https://www.newsfilecorp.com/release/49248

!
Thumb 8020 monitor 200200 2

8020 Admin

4 days ago

8020 Admin posted a press release Beleave Appoints Jeannette VanderMarel Chief Executive Officer in BELEAVE KANNABIS CORP.

Toronto, Ontario--(Newsfile Corp. - October 28, 2019) - Beleave's (CSE: BE) (OTCQX: BLEVF) ("Beleave" or the "Company") Board of Directors announced that Jeannette VanderMarel has been appointed the Company's Chief Executive Officer. Bill Panagiotakopoulos, who took over as CEO earlier this year, will return to his role as Beleave's COO. These changes are effective today.


"I am proud and thrilled to be adding my skills and investment to the Beleave team," said Ms. VanderMarel. "This is an exciting time in the cannabis marketplace and our investors, employees, partners, and customers are looking for us to drive innovation and growth in this new era. Beleave is ideally positioned to capitalize on the many opportunities that are ahead of us, and I'm excited to be working with the leadership team to realize that potential."


"Jeannette has a phenomenal track-record and has been instrumental in originating and building successful businesses for years in the cannabis sector. She has a strong command of our industry and a proven ability to drive results," said Kevin Keagan, interim CFO at Beleave. "I am proud that Jeannette will lead our company, and our entire leadership team is excited to work with her to ensure a seamless transition as we move towards Beleave's next phase of growth and market leadership."


As an early mover in the Canadian cannabis industry, Ms. VanderMarel was the Co-CEO of 48 North Cannabis, Co-Founder and President of Good & Green, and Co-Founder of The Green Organic Dutchman. Motivated by her first-hand experience, Jeannette has a strong passion for, and commitment to, the cannabis industry, recognizing the opportunity cannabis presents to improve patients' lives, combat the growing reliance on opiates, and improve wellness and health by offering new and innovative treatment alternatives. She is a certified CNCCP(C) through the Canadian Nurses Association, registered nurse, popular keynote speaker, and makes frequent TV and print media appearances as she shares her thoughts and knowledge on cannabis-related news.


"At the same time, we are happy that we will continue to benefit from Bill's experience as he returns to his role as Beleave's Chief Operations Officer," added Keagan. "He has been an exemplary leader during this time of transition, with a steadfast commitment to driving Beleave's business and building on our strong momentum. We are grateful for his leadership and stewardship. With Jeannette as CEO and Bill as COO, Beleave has a great advantage in our marketplace."


ABOUT BELEAVE INC.


Beleave is an ISO certified, Canadian cannabis company headquartered in the Greater Toronto Area that cultivates high-quality cannabis flower, oil and extracts for medical and recreational markets. Beleave is fully licenced to cultivate and sell medical and recreational cannabis and is leading the way through research partnerships with universities to develop pharma-grade extracts and derivatives.


Beleave is developing new product lines, including cannabis-infused products, oils, vape pens, and other novel cannabis delivery methods for 2019. Beleave has developed a network of medical cannabis clinics in Ontario and Quebec under the Medi-Green banner. Beleave has partnered with Canymed GmbH to supply the German market with medical cannabis


Investor Relations Contact:
Kevin Keagan
Interim Chief Financial Officer
Phone: 1 (647) 449 - 7352
Email: kkeagan@beleave.com


Forward-Looking Statements


This news release contains "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). The use of any of the words "plan", "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and other similar words, or statements that certain events or conditions "may" or "will" occur are intended to identify forward-looking information. These statements are only predictions. Although the Company believes that the expectations and assumptions on which the forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature it involves inherent risks and uncertainties. This information speaks only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents, which can be found under the Company's profile on www.sedar.com.



To view the source version of this press release, please visit https://www.newsfilecorp.com/release/49179

!